Mindfulness, Fibromyalgia, Stress
Conditions
Brief summary
This study is a double-blinded randomized controlled trial with two arms, comparing a recorded mindfulness intervention to a control psycho-education audio. It is a monocentric study that will take place in Centre Hospitalier Universitaire Vaudois (CHUV), a primary teaching hospital in Lausanne, Switzerland. Patients will be randomized 1:1 to the brief mindfulness intervention vs neutral audio intervention. The investigators involved in recruitment and testing will be blind to the intervention condition. A collaborator that is not involved in this study will prepare a coded randomized sequence of audio assignments, uploaded in Redcap. The audio will be played on a laptop or mp-player with a noise cancelling headset.
Interventions
BEHAVIORALMindfulness
One session of a 20 minute mindfulness recording, based on standardised script, focused on stress management.
BEHAVIORALPsycho-education
One session of a 20 minute recording, based on standardised script, focused on psychophysiological stress response description.
Sponsors
University of Lausanne Hospitals
Study design
Allocation
NA
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* We plan to recruit adult female patients (\>18 years old) suffering from fibromyalgia (FMS), with chronic pain (more than 6 months), willing and able to give informed consent. Specifically, patients must fulfil the criteria of the American College of Rheumatology (2010) by having the following combination of scores at the widespread pain index (WPI) and the severity score (SS) : * WPI score is ≥7 and the SS score is ≥ 5 OR * WPI score is comprised between 3 to 6 and the SS score ≥9 * And no other condition explaining the painful syndrome
Exclusion criteria
* Insufficient French language skills * Unstable psychiatric co-morbidity: major depression with current suicidal risk, unstable psychotic disorder, unstable psychotropic medication (stable=more than 3 month under the same dose). * Somatic co-morbidity that could interfere with physiological monitoring/stress tolerance: such as cardiac malformation, recent myocardial dysfunction, cardiac transplantation, or cardiac treatment (pacemaker, antiarrhythmic drugs, muscarinic receptor blockers, ACE inhibitors or any that would induce a modification in HR) * Contraindication to sensors positioning (local skin damage or allergies) * Substance use disorder (alcohol, drugs). * Refusal to listen to an audio recording of mindfulness
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Perceived stress reactivity | Within 3 hours | The primary outcome is the variation of perceived stress level along the task. A 2-way repeated-measures ANOVA will be conducted to compare the stress reactivity of patients receiving the mindfulness intervention and the control intervention. Perceived stress will be measured using visual analog scales from 0 to 10, 0 meaning no stress perceived and 10 meaning the highest stress perceived. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Respiration rate | Within 3 hours | Respiration rate will also be measured using a NeXus-10 MKII, Mindmedia with a thoracic belt. A 2-way repeated-measures ANOVA will be conducted to compare the respiration rate of patients receiving the mindfulness intervention and the control intervention. |
| Oxygen saturation | Within 3 hours | Oxygen saturation will also be measured using a NeXus-10 MKII, Mindmedia with a pulse oximeter probe. A 2-way repeated-measures ANOVA will be conducted to compare the oxygen saturation of patients receiving the mindfulness intervention and the control intervention. |
| Electrodermal activity | Within 3 hours | Electrodermal activity will also be measured using a NeXus-10 MKII, Mindmedia with two fingertips electrodes. A 2-way repeated-measures ANOVA will be conducted to compare the electrodermal activity of patients receiving the mindfulness intervention and the control intervention. |
| Heart rate variability | Within 3 hours | Heart rate variability will also be measured using a NeXus-10 MKII, Mindmedia with 3 electrodes. A 2-way repeated-measures ANOVA will be conducted to compare the heart rate variability of patients receiving the mindfulness intervention and the control intervention. |
| Salivary cortisol concentrations | Within 3 hours | Salivary cortisol concentration will also be collected using a mouth cotton swab. A 2-way repeated-measures ANOVA will be conducted to compare the salivary cortisol concentrations of patients receiving the mindfulness intervention and the control intervention. |
| Blood catecholamine levels | Within 3 hours | Blood catecholamine levels will also be collected using a venous line on the non-dominant arm for repeated blood collection. A 2-way repeated-measures ANOVA will be conducted to compare the blood catecholamine levels of patients receiving the mindfulness intervention and the control intervention. |
| Cerebral activity | Within 3 hours | Cerebral activity will also be measured using a 6-electrodes headband electroencephalogram (Dreem headband, Dreem SAS). |
Countries
Switzerland
Outcome results
None listed